High altitude pulmonary hypertension: overlap with other types of pulmonary hypertension and implications for treatment
Abstract
High altitude pulmonary hypertension occurs in a subset of the 80-140 million people who live at altitudes ≥2500 m. This type of pulmonary hypertension is generally defined by a mean pulmonary artery pressure >30 mm Hg and is associated with symptoms of exercise intolerance, with possible progression to right heart failure. High altitude pulmonary hypertension can be difficult to distinguish from other forms of pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension caused by lung disease. In theory, removal from high altitude effectively treats high altitude pulmonary hypertension but not pulmonary arterial hypertension and pulmonary hypertension caused by lung disease. In reality, mechanistic overlap between the diseases exists, and the clinical phenotypes may likewise overlap. Limited evidence exists for other treatments for high altitude pulmonary hypertension, with the greatest rationale currently for pulmonary vasodilators. Future research should revisit the diagnostic threshold for high altitude pulmonary hypertension and for other forms of pulmonary hypertension at high altitude. Also, more research is needed to better differentiate between patients living at high altitude with high altitude pulmonary hypertension and those with other forms of pulmonary hypertension, and to define which treatments can be extrapolated from other types of pulmonary hypertension to high altitude pulmonary hypertension.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.